A new review article published in the World Journal of Pediatrics outlines a genetic framework called Behçet's spectrum disorders (BSD) to help clinicians diagnose and treat children with inflammatory symptoms that resemble Behçet's disease but do not meet standard criteria. The framework, developed by researchers at Peking Union Medical College Hospital in Beijing, aims to reduce diagnostic delays and guide genetic testing for early-onset or atypical cases.
Behçet's disease is a systemic vasculitis characterized by recurrent oral and genital ulcers, but pediatric presentations are often partial or atypical, complicating diagnosis. In addition, monogenic autoinflammatory disorders can produce nearly identical mucocutaneous and gastrointestinal symptoms, leading to misdiagnosis and inappropriate treatment. The BSD concept, first introduced in 2020, links these conditions through shared immune pathways, but a practical clinical framework has been lacking until now.
The review, published online June 23, 2026 (DOI: 10.1007/s12519-026-01035-4), proposes a two-tier classification: core BSD for monogenic diseases that directly converge on Behçet's-defining inflammatory pathways, and peripheral BSD for conditions with partial clinical overlap or indirect mechanistic connections. Core BSD includes HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency—all disrupting NF-κB or JAK-STAT signaling. Peripheral BSD encompasses polygenic or multifactorial entities such as recurrent aphthous stomatitis, PFAPA syndrome, DADA2, and trisomy 8-associated disease.
“We're not saying these are all the same disease—they're not. But they converge on the same inflammatory circuits,” the authors said. “If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn't quite fit Behçet's criteria, the BSD framework gives us a roadmap for what to test for and why.” The framework is especially valuable in early-onset or atypical cases, where genetic testing can distinguish between conditions that look alike but respond to very different treatments.
The researchers emphasize that the framework does not replace existing diagnostic criteria but offers a mechanism-oriented lens to prioritize genetic testing, reducing diagnostic odysseys. Clinically, it enables earlier recognition of Behçet-like phenotypes and guides targeted therapies—such as IL-1, TNF, or JAK inhibitors—for specific subsets. It also helps exclude non-spectrum mimics like LIG4 deficiency and IKBKG (NEMO) mutations, avoiding unnecessary investigations.
Scientifically, the framework unifies disparate inflammatory disorders under shared pathogenic axes, fostering collaborative research and biomarker discovery. The study was supported by the National Key R&D Program of China and other grants. The World Journal of Pediatrics, with an Impact Factor of 7.3, is a peer-reviewed journal dedicated to advancing pediatric medicine.
